製藥 業務的一部分 生命科學.
人們仰賴製藥產業提供改善生活品質的救命藥物和治療方法。即使在研發上投入數十億美元,也只有少許新藥能通過臨床試驗和符合進入市場所需的嚴格監管許可。對於這樣的企業,至關重要的是,公司必須保護奠基新藥和療法的智慧財產。Finnegan飛翰與創新的製藥公司合作已有悠久的歷史,旨於保護和最大化其寶貴的智財權與資產,為智財申請和組合擬訂策略。
我們客戶的業務和智財資產是全球性的,在各轄區保護這些資產變得越來越挑戰。結合我們在全球設立的據點和與跨國公司的合作經驗,Finnegan飛翰擁有的資源和經驗,得以為製藥公司制訂及執行全球戰略。因應新發現及其商業應用的快速進展,需要對智財權的法律議題和產業的理解能夠充分掌握,以洞悉這些進步的科學和戰略意涵。
憑藉為製藥客戶解決幾乎各類型之智財議題的經驗,我們透過以下方式提供協助:
我們與客戶一起在眾多領域中致力科學的創新與推進,包括:
我們的生命科學業務由250多位律師和專業人士組成,致力於滿足客戶對於智財權服務的需求。多數擁有與生物學,化學,生物化學,醫學,藥理學,或生醫工程等相關學科的高階學位。大多具有紮實的研究和/或產業經驗,許多人在產業或大學任職,或在美國專利商標局擔任審查委員後加入Finnegan飛翰。
Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.
Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.
Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.
Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.
Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.
Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer.
At the PTAB Blog
Squires Issues Precedential Decision Clarifying Obviousness-Type Double Patenting Rejections
August 17, 2026
Federal Circuit IP Blog
July 8, 2026
Award/Ranking
Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards
August 10, 2026
Award/Ranking
Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards
July 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.